DrugPatentWatch Database Preview
Profile for Spain Patent: 2351709
» See Plans and Pricing
US Patent Family Members and Approved Drugs for Spain Patent: 2351709
US Patent Number | US Expiration Date | US Applicant | US Tradename | Generic Name |
---|---|---|---|---|
Start Trial | Dec 5, 2029 | Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride |
Start Trial | Nov 22, 2025 | Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride |
Start Trial | Nov 22, 2025 | Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride |
Start Trial | Nov 22, 2025 | Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride |
Start Trial | Nov 22, 2025 | Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride |
Start Trial | May 22, 2026 | Forest Labs Llc | NAMENDA XR | memantine hydrochloride |
Start Trial | May 22, 2026 | Allergan | NAMZARIC | donepezil hydrochloride; memantine hydrochloride |
>US Patent Number | >US Expiration Date | >US Applicant | >US Tradename | >Generic Name |